Current Fellows' Research & Clinical Interests

First Year

  • Alfred Chung, MD (Hematology/Oncology)
  • Asiri Ediriwickrema, MD, MHS (Hematology/Oncology)
  • Jessica A. Hellyer, MD (Oncology)
  • Marie A. Hollenhorst, MD, PhD (Hematology)
  • Yasmin H. Karimi, MD (Hematology/Oncology)
  • Daniel Alexander King, MD, PhD (Oncology)
  • Lydia Mandrussow, MD (Hematology/Oncology)
  • Eric Mou, MD (Hematology/Oncology)
  • Jay Spiegel, MD (Hematology)

Second Year

  • John Baird, MD (Hematology/Oncology)
  • Evan Hall, MD, MPhil (Hematology/Oncology)
  • Nathaniel Myall, MD (Hematology/Oncology)
  • Shyam A. Patel, MD, PhD (Hematology/Oncology)
  • William Shomali, MD (Hematology/Oncology)
  • Michael Spinner, MD (Hematology/Oncology)
  • Diane Tseng, MD, PhD (Oncology)

Third Year

  • Alexey Aleshin, MD, MBA (Peter Greenberg, Hematology/Oncology)
  • Viola Chen, MD (Alice Fan, Oncology/ Shan Wang, Electrical Engineering)
    Using nanotechnology to profile renal cell carcinoma circulating tumor cells
  • Brian Dietrich, MD (Hematology/ Sandy Srinivas, Oncology)
  • Gregory Kaufman, MD (Michaela Liedtke, Hematology/Oncology)
  • Michael Mancuso, MD, PhD (Hematology/Ash Alizadeh, Oncology)
  • Brian Sworder, MD, PhD (Hematology/Ash Alizadeh, Oncology)
  • Jeffrey Zweig, MD (Hematology/Heather Wakelee, Oncology)

Fourth Year

  • Jennifer Caswell-Jin, MD (Christina Curtis, Oncology and Genetics/ Allison Kurian, Oncology and Health Research & Policy)
    Genomics of breast tumor response to treatment
  • Adel Kardosh, MD, PhD (Hematology/ Ronald Levy & George Fisher, Oncology)
    Cancer immunology in solid malignancies
  • Wendy Pang, MD, PhD (Hematology/ Irving Weissman, Pathology & Stem Cell Biology/ Judith Shizuru, BMT)
    Targeting blood-forming stem cells in myelodysplastic syndrome
  • Tanaya Shree, MD, PhD (Hematology/ Ron Levy, Oncology)
  • Tian Yi Zhang, MD, PhD (Ravi Majeti, Hematology)
    Deciphering the cause of cytopenias in AML

Fifth Year

  • Matthew Frank, MD, PhD (Hematology/ Ronald Levy, Oncology)
    Novel treatment strategies in lymphoma
  • Ameen A. Salahudeen, MD, PhD (Calvin Kuo, Hematology/ Oncology)
    Modeling aerodigestive malignancies through primary organoid culture


David M. Kurtz, MD (Hematology/ Ash Alizadeh, Oncology/ Sanjiv Gambhir, Radiology)
ARTS (Advanced Residency Training Program) Bioengineering PhD Program
Monitoring therapeutic responses in lymphoma

Current Instructors' Research & Clinical Interests

  • Mark P. Chao, MD, PhD (Irving Weissman, Pathology; Jason Gotlib, Hematology)
    Modeling hematologic malignancies through induced pluripotent stem cells
  • Joshua Gruber, MD, PhD (James Ford, Oncology; Michael Snyder, Genetics)
    Measuring somatic mutation rate in patients at high risk for malignancy
  • Robert W. Hsieh, MD, PhD (Michael Clarke, Oncology)
    RNAi screening in primary human breast cancer cells to identify regulators in oncogenic growth
  • Michael Khodadoust, MD, PhD (Ronald Levy & Ash Alizadeh, Oncology)
    Anti-tumor immune responses in lymphoma
  • Yu Wong, MD, PhD (Mark Davis, Microbiology & Immunology)
    Design of novel approach to measure T cell repertoire. Translational research in breast cancer